The Medacta International AMIStem-P Post-Marketing Surveillance Study
Prospective, Multicentre, Open Study Evaluating the Performance and Stability of the AMIStem-P Femoral Stem
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Blendecques, France, 62575
- Clinique de Saint Omer
-
Castres, France, 81108
- Hôpital Castres
-
Floirac, France, 33270
- Nouvelle Clinique Bordeaux Tondu
-
Orange, France, 84100
- Clinique d'Orange
-
Rodez, France, 12000
- Hôpital Jacques-Puel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with a disease (primary coxarthrosis, inflammatory arthritis of the hip, necrosis of the femoral head, etc.) requiring a total hip replacement
- Patient eligible to receive an uncemented AMIStem-P femoral stem
- Patient agreeing to comply with the study requirements
- Patient willing to provide written informed consent
- Patient affiliated to a social security system
- Patients between 18 and 85 years old
Exclusion Criteria:
- Participation in biomedical research
- Patients younger than 18 years old
- Vulnerable adult patients according to article L1121-6 of the French Public Health Code
- Pregnant or breastfeeding women
- Patients unable to provide written informed consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival rate
Time Frame: 10 years
|
Kaplan Meier method
|
10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiographic performance of the implants
Time Frame: 3/6 months, 1, 3, 5 and 10 years
|
Presence of radiolucencies, migration, loosening, subsidence, tilt
|
3/6 months, 1, 3, 5 and 10 years
|
|
Adverse events
Time Frame: intraop, 3/6 months, 1, 3, 5 and 10 years
|
Intraoperative and postoperative adverse events
|
intraop, 3/6 months, 1, 3, 5 and 10 years
|
|
Harris Hip Score
Time Frame: 3/6 months, 1, 3, 5 and 10 years
|
Harris Hip Score [min = 0 (worst clinical outcome), max = 100 (best clinical outcome)]
|
3/6 months, 1, 3, 5 and 10 years
|
|
Oxford Hip Score
Time Frame: 3/6 months, 1, 3, 5 and 10 years
|
Oxford Hip Score [min = 0 (worst functional outcome), max = 48 (best functional outcome)]
|
3/6 months, 1, 3, 5 and 10 years
|
|
Quality of life - Euroqol questionnaire
Time Frame: 3/6 months, 1, 3, 5 and 10 years
|
EQ-5D-5L score [min = -0.59
(worst functional outcome), max = 1 (best functional outcome)]
|
3/6 months, 1, 3, 5 and 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alexandru Nebunescu-Schirliu, MD, Hôpital Jacques-Puel
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P01.001.16
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.